多西他赛联合卡培他滨治疗复发转移性乳腺癌的疗效及对CEA、CA199的影响  

Efficacy of docetaxel combined with capecitabine in the treatment of recurrent metastatic breast cancer and its effect on CEA and CA199

作　　者：胡米 Hu Mi(Changsha Central Hospital Affiliated to Nanhua University,Changsha,Hunan 410004,China)

机构地区：[1]南华大学附属长沙中心医院,湖南长沙410004

出　　处：《首都食品与医药》2023年第12期64-66,共3页Capital Food Medicine

摘　　要：目的研究复发转移性乳腺癌采用多西他赛联合卡培他滨治疗的疗效及对癌胚抗原(CEA)、糖类抗原199(CA199)的影响。方法此次研究的开展时间在2021年7月-2022年9月,将该时间段内在南华大学附属长沙中心医院接受治疗的70例复发转移性乳腺癌患者作为研究对象,按照随机数字表法将上述患者设置为观察组(n=35,采取多西他赛联合卡培他滨治疗)与对照组(n=35,采取卡培他滨治疗),对比两组的临床疗效。结果从两组的临床疗效、肿瘤标志物水平、不良反应发生情况以及KPS评分、肿瘤进展时间和中位生存期进行对比分析,在经过治疗后,观察组的临床控制有效率、临床有效率、KPS评分都要高于对照组,CEA、CA125、CA199、CA153水平以及脱发发生率观察组低于对照组,肿瘤进展时间和中位生存期观察组长于对照组,差异均有统计学意义(P<0.05)。结论在复发转移性乳腺癌的临床治疗中,采用多西他赛联合卡培他滨治疗具有良好的应用优势,可有效控制疾病发展,延长患者的生存周期,具有较高的推广价值。Objective To study and analyze the efficacy of docetaxel combined with capecitabine in the treatment of recurrent and metastatic breast cancer and its effects on carcinoembryonic antigen(CEA)and carbohydrate antigen 199(CA199).Method This study was carried out from July 2021 to September 2022.70 patients with recurrent and metastatic breast cancer who received treatment in our hospital during this period were selected as research objects.According to random number table method,these patients were divided into observation group(n=35,docetaxel combined with capecitabine)and control group(n=35,treatment with capecitabine),the clinical efficacy of the two groups was compared.Results The clinical efficacy,tumor marker level,occurrence of adverse reactions,KPS score,tumor progression time and median survival of the two groups were compared and analyzed.After treatment,the clinical control effectiveness,clinical effective rate and KPS score of the observation group were higher than those of the control group.The levels of CEA,CA125,CA199,CA153 and the incidence of alopecia in the observation group were lower than those in the control group,and the observation of tumor progression time and median survival time was longer than that in the control group,with statistical significance(P<0.05).Conclusion In the clinical treatment of recurrent and metastatic breast cancer,docetaxel combined with capecitabine has good application advantages,which can effectively control the development of the disease and prolong the survival cycle of patients,and has high promotion value.

关 键 词：多西他赛 卡培他滨 复发转移性乳腺癌 CEA CA199 

分 类 号：R737.9[医药卫生—肿瘤]